BMY financials
Bristol-Myers Squibb Company · end-of-day data as of Oct 16, 2026
Bristol-Myers Squibb Company
$59.75-2.8%
Hold · 30 analystsPT $65.38 +9.4%
BMY reported revenue of $12.97B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 5.7% from a year earlier. It posted diluted EPS of $1.62, free cash flow of $3.09B and a net margin of 25.6%.
Valuation
- P/E13.2x
- P/E vs own-13.2%
- P/E vs sector-53.3%
- FCF yield+9.4%
- Market cap$122B
Quarterly results
Q2 FY2026: Revenue +5.7% year over year, free cash flow 23.8% of revenue, operating margin 31.0%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $12.97B | 1.62 | $3.09B | 71.3% | 31.0% | 25.6% |
| Q1 FY2026 | Mar 31, 2026 | $11.49B | 1.31 | $757M | 70.2% | 29.3% | 23.3% |
| Q4 FY2025 | Dec 31, 2025 | $12.5B | 0.53 | $1.6B | 67.2% | 22.5% | 8.7% |
| Q3 FY2025 | Sep 30, 2025 | $12.22B | 1.08 | $5.99B | 71.9% | 29.8% | 18.0% |
| Q2 FY2025 | Jun 30, 2025 | $12.27B | 0.64 | $3.56B | 72.5% | 30.8% | 10.7% |
| Q1 FY2025 | Mar 31, 2025 | $11.2B | 1.20 | $1.69B | 72.9% | 31.2% | 21.9% |
| Q4 FY2024 | Dec 31, 2024 | $12.34B | 0.04 | $4.06B | 61.0% | 4.1% | 0.6% |
| Q3 FY2024 | Sep 30, 2024 | $11.89B | 0.60 | $5.27B | 75.1% | 18.3% | 10.2% |
| Q2 FY2024 | Jun 30, 2024 | $12.2B | 0.83 | $2.06B | 55.7% | 21.2% | 13.8% |
| Q1 FY2024 | Mar 31, 2024 | $11.87B | -5.89 | $2.55B | 55.5% | 12.9% | -100.4% |
| Q4 FY2023 | Dec 31, 2023 | $11.48B | 0.87 | $3.92B | 56.6% | 17.0% | 15.4% |
| Q3 FY2023 | Sep 30, 2023 | $10.97B | 0.93 | $4.41B | 56.7% | 19.2% | 17.6% |